Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Sonoma Pharmaceuticals stock | $6.21

Own Sonoma Pharmaceuticals stock in just a few minutes.

Fact checked

Sonoma Pharmaceuticals, Inc is a drug manufacturers-specialty & generic business based in the US. Sonoma Pharmaceuticals shares (SNOA) are listed on the NASDAQ and all prices are listed in US Dollars. Sonoma Pharmaceuticals employs 19 staff and has a trailing 12-month revenue of around USD$21.3 million.

How to buy shares in Sonoma Pharmaceuticals

  1. Compare share trading platforms. If you're a beginner, look for a platform with low commissions, expert ratings and investment tools to track your portfolio. Narrow down top brands with our comparison table.
  2. Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and bank information. Fund your account with a bank transfer, credit card or debit card.
  3. Search for Sonoma Pharmaceuticals. Find the stock by name or ticker symbol: SNOA. Research its history to confirm it's a solid investment against your financial goals.
  4. Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until Sonoma Pharmaceuticals reaches your desired price. To spread out your purchase, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
  5. Decide on how many to buy. At last close price of USD$6.21, weigh your budget against a diversified portfolio that can minimize risk through the market's ups and downs. You may be able to buy a fractional share of Sonoma Pharmaceuticals, depending on your broker.
  6. Check in on your investment. Congratulations, you own a part of Sonoma Pharmaceuticals. Optimize your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.

Sonoma Pharmaceuticals share price

Use our graph to track the performance of SNOA stocks over time.

Sonoma Pharmaceuticals shares at a glance

Information last updated 2020-12-07.
Latest market closeUSD$6.21
52-week rangeUSD$3.55 - USD$9.89
50-day moving average USD$7.3074
200-day moving average USD$7.535
Wall St. target priceUSD$9
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) USD$-7.062

Buy Sonoma Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Stock trade fee Asset types Option trade fee Annual fee
Sofi Invest
$0
Stocks, ETFs, Cryptocurrency
N/A
0%
A free way to invest in stocks, ETFs and crypto.
Interactive Brokers
$0
Stocks, Forex
$0 + $0.65/contract, $1 minimum
0%
IBKR Lite offers $0 commissions, and IBKR Pro offers advanced tools for professional traders.
Public
$0
Stocks, ETFs
N/A
Robinhood
$0
Stocks, Options, ETFs, Cryptocurrency
$0
0%
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
$0 for US stocks
Stocks, Options, ETFs
$0
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Sonoma Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Sonoma Pharmaceuticals price performance over time

Historical closes compared with the close of $6.21 from 2020-12-09

1 week (2021-01-12) N/A
1 month (2020-12-23) -24.08%
3 months (2020-10-19) N/A
6 months (2020-07-19) N/A
1 year (2020-01-19) N/A
2 years (2019-01-19) N/A
3 years (2018-01-19) N/A
5 years (2016-01-19) N/A

Sonoma Pharmaceuticals financials

Revenue TTM USD$21.3 million
Gross profit TTM USD$8.3 million
Return on assets TTM -14.98%
Return on equity TTM -26.47%
Profit margin -9.87%
Book value $5.664
Market capitalisation USD$13.9 million

TTM: trailing 12 months

Shorting Sonoma Pharmaceuticals shares

There are currently 6,957 Sonoma Pharmaceuticals shares held short by investors – that's known as Sonoma Pharmaceuticals's "short interest". This figure is 18.2% down from 8,506 last month.

There are a few different ways that this level of interest in shorting Sonoma Pharmaceuticals shares can be evaluated.

Sonoma Pharmaceuticals's "short interest ratio" (SIR)

Sonoma Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Sonoma Pharmaceuticals shares currently shorted divided by the average quantity of Sonoma Pharmaceuticals shares traded daily (recently around 17392.5). Sonoma Pharmaceuticals's SIR currently stands at 0.4. In other words for every 100,000 Sonoma Pharmaceuticals shares traded daily on the market, roughly 400 shares are currently held short.

However Sonoma Pharmaceuticals's short interest can also be evaluated against the total number of Sonoma Pharmaceuticals shares, or, against the total number of tradable Sonoma Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Sonoma Pharmaceuticals's short interest could be expressed as 0% of the outstanding shares (for every 100,000 Sonoma Pharmaceuticals shares in existence, roughly 0 shares are currently held short) or 0.0034% of the tradable shares (for every 100,000 tradable Sonoma Pharmaceuticals shares, roughly 3 shares are currently held short).

Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Sonoma Pharmaceuticals.

Find out more about how you can short Sonoma Pharmaceuticals stock.

Sonoma Pharmaceuticals share dividends

We're not expecting Sonoma Pharmaceuticals to pay a dividend over the next 12 months.

Have Sonoma Pharmaceuticals's shares ever split?

Sonoma Pharmaceuticals's shares were split on a 1:9 basis on 20 June 2019. So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Sonoma Pharmaceuticals shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Sonoma Pharmaceuticals shares which in turn could have impacted Sonoma Pharmaceuticals's share price.

Sonoma Pharmaceuticals share price volatility

Over the last 12 months, Sonoma Pharmaceuticals's shares have ranged in value from as little as $3.55 up to $9.89. A popular way to gauge a stock's volatility is its "beta".

SNOA.US volatility(beta: 0.76)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Sonoma Pharmaceuticals's is 0.757. This would suggest that Sonoma Pharmaceuticals's shares are less volatile than average (for this exchange).

Sonoma Pharmaceuticals overview

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for various applications, including wound care, animal health care, eye care, oral care, and dermatological conditions in the United States and internationally. The company offers Epicyn, an antimicrobial facial cleanser; Levicyn, a hypochlorous acid (HOCl) based prescription product to manage and relieve burning, itching, and pain experienced with various types of dermatoses; Celacyn gel, a product indicated to promote healing through the management of new and old scars resulting from surgical procedures and trauma wounds or burns; SebuDerm, a product indicated to manage and relieve the burning, itching, pain, and distraction associated with seborrhea and seborrheic dermatitis; and Ceramax, a Lipogrid based skin barrier cream for management of dry itchy skin, minor skin irritations, rashes, and inflammation caused by various skin conditions, as well as Loyon for the management of skin scaling. It also provides Acuicyn, a HOCl-based product indicated to relieve itch and inflammation while helping to keep areas around the eye clean; and Microcyn, a line of products designed to stimulate expedited healing by targeting various pathogens, as well as antibiotic-resistant strains that slow natural healing of wounds. In addition, the company offers MicrocynAH and MicrocynVS, which are HOCl-based solutions designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; Pediacyn, Epicyn, Gramaderm, and Microdacyn for dermatoses, scar management, and acne; and Sinudox for nasal irrigation, including moistening of cuts, abrasions, and lacerations located in the nasal cavity. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Woodstock, Georgia.

Frequently asked questions

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site